

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/569,159
Filing Date	February 21, 2006
First Named Inventor	Dawn Patricia Wooley
Art Unit	
Examiner Name	
Attorney Docket Number	WRU 0255 PA/40878.341

Sheet 1 of 2

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-2003/0119764 A1	06-26-2003	Loeb et al.	
		US-2003/0054339 A1	03-20-2003	Smet et al.	
		US-2002/0037500 A1	03-28-2002	Whitcomb	
		US-6,265,152 B1	07-24-2001	Dunn et al.	
		US-6,242,187 B1	06-05-2001	Capon et al.	
		US-6,187,538 B1	02-13-2001	Eastman et al.	
		US-6,063,562	05-16-2000	Melnick et al.	
		US-6,132,776	10-17-2000	Loeb et al.	
		US-6,130,036	10-10-2000	Loeb et al.	
		US-6,063,628	05-16-2000	Loeb et al.	
		US-6,007,983	12-28-1999	Dunn et al.	
		US-5,827,648	10-27-1998	Eastman et al.	
		US-5,665,569	09-09-1997	Ohno	
		US-5,512,431	04-30-1996	Loeb et al.	
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		WO 02/070731 A2	09-12-2002	Lloyd et al.		
		WO 02/33638 A2	04-25-2002	Dehertogh et al.		

Examiner Signature	/Michael Burkhardt/	Date Considered	03/10/2011
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/569,159		
		<b>Filing Date</b>	February 21, 2006		
		<b>First Named Inventor</b>	Dawn Patricia Wooley		
		<b>Art Unit</b>			
		<b>Examiner Name</b>			
Sheet	2	of	2	<b>Attorney Docket Number</b>	WRU 0255 PA/40878.341

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LOUIS M. MANSKY, ERWANN LE ROUZIC, SERGE BENICHO, LISA C. GAJARY, "Influence of Reverse Transcriptase Variants, Drugs, and Vpr on Human Immunodeficiency Virus Type 1 Mutant Frequencies," Journal Of Virology, February 2003, pages 2071-2080, Vol. 77, No. 3, American Society for Microbiology, USA	
		L.A. BIRCHER, J.C. RIGANO, V.G. PONFERRADA, D.P. WOOLEY, "High Fidelity of Homologous Retroviral Recombination in Cell Culture," Archives of Virology, July 22, 2002, pages 1665-1683, USA	
		LOUIS M. MANSKY, SANDRA PREVERAL, LUC SELIG, RICHARD BENAROUS, SERGE BENICHO, "The Interaction of Vpr with Uracil DNA Glycosylase Modulates the Human Immunodeficiency Virus Type 1 In Vivo Mutation Rate," Journal of Virology, August 2000, pages 7039-7047, Vol. 74, No. 15, American Society of Microbiology, USA	
		DAWN P. WOOLEY, LISA A. BIRCHER, RANDALL A. SMITH, "Retroviral Recombination Is Nonrandom and Sequence Dependent," Article No. VY989052, January 23, 1998, pages 229-234, Academic Press, USA	
		JEFFREY A. ANDERSON, ELLA HARVEY BOWMAN, WEI-SHAU HU, "Retroviral Recombination Rates Do Not Increase Linearly with Marker Distance and Are Limited by the Size of the Recombining Subpopulation," Journal Of Virology, February 1998, pages 1195-1202, Vol. 72, No. 2, American Society of Microbiology, USA	
		LOUIS M. MANSKY, HOWARD M. TEMIN, "Lower In Vivo Mutation Rate of Human Immunodeficiency Virus Type 1 than That Predicted from the Fidelity of Purified Reverse Transcriptase," Journal of Virology, August 1995, pages 5087-5094, Vol. 69, No. 8, American Society for Microbiology, USA	

<b>Examiner Signature</b>	/Michael Burkhardt/	<b>Date Considered</b>	03/10/2011
---------------------------	---------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.